lobbying_activities: 1144491

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1144491	6b94c7f8-f4cb-4523-9af6-5c84d4f80955	Q3	TAKEDA PHARMACEUTICALS AMERICA, INC.	57954	TAKEDA PHARMACEUTICALS AMERICA INC	2011	third_quarter	MMM	340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; Debt and deficit negotiations S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; the Medicaid Improvement and State Empowerment Act; Academic Detailing;	Agency for Healthcare Research & Quality (AHRQ),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Food & Drug Administration (FDA),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),SENATE,Treasury, Dept of		400000	0	0	2011-10-03T13:54:18.780000-04:00